Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Terbuch, A; Konjic, S; Schlintl, V; Absenger, G; Jost, PJ; Lindenmann, J; Swatek, P; John, N; John, T; Wurm, R; Zacharias, M; Posch, F; Hochmair, MJ; Fabikan, H; Weinlinger, C; Illini, O; Horvath, L; Gamerith, G; Wolf, D; Augustin, F; Brcic, L.
Prognostic impact of targetable driver alterations in resected early-stage lung cancer.
Transl Lung Cancer Res. 2024; 13(11): 3096-3105.
Doi: 10.21037/tlcr-24-433
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Brcic Luka
- Terbuch Angelika
- Co-Autor*innen der Med Uni Graz
- Absenger Gudrun
- John Nikolaus
- John Teresa
- Jost Philipp
- Konjic Selma
- Lindenmann Jörg
- Posch Florian
- Schlintl Verena
- Swatek Paul
- Wurm Robert
- Zacharias Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Apart from ALK fusions and the common EGFR mutations, targetable molecular alterations are irrelevant for adjuvant treatment decision making in early-stage non-small cell lung cancer (NSCLC). This retrospective analysis aimed to investigate if there is a difference in recurrence-free survival in stage I-III NSCLC harboring druggable molecular alterations compared to subtypes without targetable molecular alterations. METHODS: All consecutive patients who underwent surgery with curative intent for NSCLC (stage I-III) with targetable mutations between January 2015 and December 2020 at three Austrian institutions were identified and compared with tumors without targetable molecular alterations. Tumors with the EGFR-mutated subtype were excluded due to already existing results from prospective trials. RESULTS: One hundred and sixty subjects had tumors with molecular alterations and 355 subjects served as control cohort. There was a higher prevalence of female sex (P<0.001) and never-smokers (P=0.01) among patients with tumors harboring oncogenic driver mutations. The three most common alterations were the KRAS G12C mutation (n=92), ALK fusions (n=21), and the BRAF V600E mutation (n=15). The 1-, 3- and 5-year cumulative incidence of recurrence estimates were 16%, 38% and 46% in patients without molecular alterations and 16%, 38% and 48% in patients with the KRAS G12C mutation and 12%, 33% and 55% in patients with other molecular alterations, respectively (P=0.89). Univariable predictors of an increased recurrence risk were higher tumor stage (P<0.001), receipt of neoadjuvant treatment (P<0.001) and receipt of adjuvant treatment (P=0.03). The lack of association between molecular alteration status and recurrence risk prevailed after multivariable adjustment for tumor stage and perioperative treatment (P=0.82 for KRAS G12C mutation and P=0.43 for any other molecular alteration). CONCLUSIONS: NSCLC patients with resected tumors that harbor molecular alterations have the same recurrence risk as patients with tumors without molecular alterations if treated with surgery plus chemotherapy when indicated.
- Find related publications in this database (Keywords)
- Non-small cell lung cancer (NSCLC)
- early-stage
- molecular alterations
- prognosis